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THE INTERACTIVE EFFECTS OF BIOFEEDBACK-ASSISTED
STRESS MANAGEMENT AND TRAINING ACQUISITION IN PREDICTING
HEALTH OUTCOME

CARY M. SEARS

ABSTRACT

Thirty-seven chronic disease patients were randomized to either a biofeedbackassisted stress management (BFSM) experimental group or a usual care (UC) control
condition. It was hypothesized that participants enrolled in the BFSM treatment group
would demonstrate lower levels of norepinephrine and depression than those in the UC
control condition. It was further hypothesized that training acquisition would modify the
main effect of group assignment on depression and norepinephrine. The BFSM group
demonstrated significantly lower levels of norepinephrine than the UC group. There were
no main effects of BFSM on depression. The training acquisition X group assignment
interaction was not significant. Results are discussed in terms of providing support for a
common mechanism for the effects of BFSM on health outcomes in chronic diseases with
ANS dysfunction, and the implications of assessing training acquisition in both clinical
and research settings.
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CHAPTER I

INTRODUCTION

Purpose of Thesis
The two purposes of this thesis are to extend the literature regarding the health
outcomes of biofeedback on patients with chronic illness, and to test the interactive
effects of biofeedback-assisted stress-management (BFSM) and training acquisition in
predicting health outcomes, in comparison to a usual care (UC) control group.
A number of chronic illnesses, including multiple sclerosis (MS) and coronary
artery disease (CAD), involve dysregulation of the autonomic nervous system (ANS).
ANS imbalance includes over-activation of the sympathetic branch and under-activation
of the parasympathetic nervous system. High sympathetic nervous system arousal and
low parasympathetic control are predictive of worse health outcomes in CAD (Carney et
al., 2005). Autonomic dysfunction, of this type, is also observed in MS (Merico et al.,
2005).
Biofeedback is a non-invasive and patient-centered self-regulatory therapy that
can assist in the treatment of chronic illness, particularly those illnesses related to
1

dysregulation of the ANS. This thesis aims to extend the research on biofeedback health
outcomes to two less frequently studied chronic disease populations, CAD and MS,
which have in common ANS dysfunction.
One mechanism by which biofeedback might exert its effects is by helping
patients learn to better regulate their ANS and help restore a healthier balance of
sympathetic and parasympathetic control. High plasma norepinephrine is an indicator of
increased sympathetic nervous system activity (Goldstein et al., 1983). It is therefore
hypothesized that participants who receive BFSM will have lower levels of plasma
norepinephrine than a usual UC control group.
Patients with chronic illness tend to be more prone to depression than physically
healthy individuals. Disruption of work and family life, financial concerns, uncertainty
regarding prognosis or when flare-ups will occur, pain and potential disability are just
some of the many issues with which patients with chronic illness may contend. High
levels of depression have been observed in both CAD (Carney et al., 2005) and MS
(Siegert & Abernathy, 2005). It is further hypothesized that biofeedback will decrease
depression in patients with chronic illness. Specifically, it is predicted that BFSM will
decrease depression, such that those in the BFSM treatment group will have lower levels
of depression than those in the UC group.
A second aim of this study is to assess the interactive effects of BFSM and
training acquisition on health outcomes. There is much evidence for the efficacy of
biofeedback. However, the literature does contain some mixed results. Some of this
variation may be due to a lack of systematically assessing whether patients were
successful in learning to alter their physiology in a healthy direction as a result of
2

biofeedback. Therefore, a training acquisition measure was developed for this study. The
training acquisition variable measures the extent to which participants are able to move
their physiology in a healthy direction in the absence of feedback. It is hypothesized that
training acquisition will interact with BFSM vs. UC to predict health outcomes.
Specifically, it is predicted that training acquisition will moderate the relationship
between group assignment (BFSM vs. UC) and norepinephrine, and depression.
Measurement of training acquisition has important implications both clinically
and in research settings. Without assessing whether participants are actually able to alter
their physiology as a result of learning biofeedback, it is difficult to determine whether
patients actually received the intended treatment, and therefore whether results, positive
or negative, are in fact due to patients actually being trained in and implementing
biofeedback. Health outcomes may be better predicted by the interaction of BFSM vs.
UC and the extent of individuals' ability to alter their physiology, or training acquisition.
Considering the cost of chronic illness to individuals' and society and the potential of
biofeedback as a cost-effective and non-invasive treatment, it is relevant to determine
variables that may interact to determine successful outcomes.

Cost of Chronic Illness
Chronic illness impacts a large number of Americans and places a high burden on
patients and their families in terms of quality of life and economic harm. Chronic illness
also negatively impacts the overall economy in terms of lost productivity and healthcare
costs. In 2012, the last year for which comprehensive data are available, 52% of
Americans had at least one chronic illness (Ward et al., 2014). The economic impact of
3

chronic disease to the United States economy is 1.3 trillion dollars annually and growing
with 1.1 trillion in lost productivity and 277 billion dollars in annual treatment costs
(DeVol & Bedroussian, 2007).

Coronary Artery Disease
Heart disease is the number one cause of death in the United States (Heron, 2015)
and coronary heart disease (CHD) or coronary artery disease (CAD) is the most prevalent
form of heart disease (CDC, 2009). CAD is a progressive and chronic condition that can
also have deleterious effects on patients' perceived quality of life including depression
(Lee, 2010)

Multiple Sclerosis
Approximately 400,000 people in the United States and 2.5 million worldwide are
diagnosed with Multiple Sclerosis (MS), a progressive, incurable, and often disabling
inflammatory disease of the Central Nervous System (Tullman, 2013). While the
symptoms and course of MS are highly variable, patients with MS often experience
fatigue, movement impairments and falls, spasticity, depression, cognitive impairment,
bowel and bladder dysfunction, sexual dysfunction, and issues with swallowing (Cheng
et al. 2010).

Biofeedback
Biofeedback is a self-regulation therapy in which individuals can gain awareness
and control of their physiology. Schwartz and Olson (2003) indicate that the term
4

“biofeedback” is shorthand for external psychophysiological feedback or physiological
feedback, and is sometimes referred to as augmented proprioception. Through
biofeedback individuals can become aware of physiological processes that are normally
beyond their awareness, and gain control over bodily functions that are not normally
under conscious control. Biofeedback falls within the larger field of applied
psychophysiology (Schwartz & Schwartz, 2003).
Biofeedback instrumentation measures processes, such as ANS activity, that are
normally outside of awareness and control. It is difficult to measure many of these
processes directly so non-invasive technology has been developed to measure correlates
(Peek, 2003). Such non-invasive technology includes electrodes on the fingers to measure
skin conductance, a correlate of sweat gland activity; finger thermisters to measure digital
peripheral temperature, a correlate of peripheral vasoconstriction; and
photoplethysmograph to measure blood volume pulse, a correlate of heart rate.
Electrocardiograms can be used to calculate heart rate variability (HRV), the variation in
the beat to beat interval between heart beats, a measure of ANS regulation.
Electromyography electrodes record electrical manifestations of muscle contraction
indicative of surface muscle tension (Peek, 2003).
Some of these parameters, such as skin conductance and digital peripheral
temperature, can be used as indications of ANS arousal. HRV can be used to assess the
balance between the sympathetic and parasympathetic branches of the ANS. These
parameters can also be used to detect disordered physiology, such as dysregulation of the
ANS. Dysregulation of the ANS is seen in hyperaurousal to stress and some disease
states (Moravec, 2008, 2011).
5

Biofeedback instruments detect minute changes in these parameters that are
normally beyond the level of conscious awareness. The signal from biofeedback
instruments is processed and fed back to the individual. Historically, feedback included
mechanical presentation of visual or auditory feedback on the state of the signal. Today
the signal is most often feedback via a computer screen that allows for presentation of
multiple channels of physiological information (McKee, 2008). Working in conjunction
with a biofeedback therapist, individuals’ learn to interpret the physiological feedback
and to alter their physiology in a healthy direction (Yucha & Montgomery, 2008).
The ultimate goal of biofeedback is for the person to learn to self-regulate
physiological processes in the absence of external feedback. The person would have
learned to alter their physiology in a healthy direction on their own. Doing so is expected
to lead to reductions in symptoms (Schwatz & Schwartz, 2003).

Heart Rate Variability (HRV) Biofeedback
HRV is used as a measure of ANS regulation. HRV is the variation in time
between heartbeats. The time period between heartbeats is referred to variously as the
interbeat interval or the RR interval where R refers to the R wave in the QRS complex of
the electrocardiogram (ECG) and RR refers to the interval of time between successive R
peaks (Bertsen et al., 1997).
Heart rate is primarily under the control of the ANS and HRV reflects the balance
of the sympathetic and parasympathetic inputs to the sinoatrial node of the heart. (Malik
et al.,1996; Billichick & Berger, 2006). Optimal heart rate variability reflects the ability
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of the healthy heart to adapt to environmental and psychological changes and challenges
and thus the adaptability or resilience of the organism (McCraty & Shaffer, 2015).
Low HRV is indicative of dysregulation of the ANS that can result from too little
parasympathetic control and/or sympathetic over-activation and has been related to
negative health outcomes (Odemuyiwa, 1994). Dysregulation of the autonomic nervous
system is involved in the pathogenesis and course of several different chronic diseases,
including those in this thesis. In HRV biofeedback patients are taught to breathe at their
resonant frequency or the breaths per minute that optimizes their HRV. Breathing is
paced on a computer screen and patients also receive feedback regarding their HRV.
While there is individual variability in resonant frequency, a typical rate of breathing to
optimize HRV is around 6 breaths per minute.

Biofeedback Models
Several historical tributaries feed into the river of modern biofeedback. These
include, but are not limited to, behavioral psychology and learning theory, cognitive
behavioral psychology and cybernetics, psychophysiology, behavioral medicine, stress
research and stress management techniques. These combined with the advent of
biomedical engineering made modern biofeedback possible (Schwartz & Olson, 2003).
One early stream of research biofeedback draws from is classical studies of
operant or instrumental conditioning of the ANS. Initially, it was believed that the ANS
could only be controlled through classical conditioning and certainly not through
conscious control (Lehrer, 2003). Instrumental conditioning is still sometimes used as a
model to explain how biofeedback works. In this model the signal fed back to the patient
7

is a reinforcer that results in operant conditioning of physiological processes beyond
conscious awareness or control (Schwartz & Olson, 2003).
Several contemporary models have been constructed to account for the learning
and change that occurs in biofeedback. McKee (2008) delineates two operative models:
The direct feedback model and the therapeutic/stress-management/biofeedback model. In
the direct feedback model patients are trained to directly alter specific physiology and it
is assumed that the direct feedback enhances leaning. This relies more on cognitive
behavioral approaches than classical conditioning. The therapeutic/stressmanagement/biofeedback model takes an individual approach, particularly with patients
who have excessive arousal related to autonomic dysfunction. Stress-management
techniques are used, along with measurement of arousal and recovery, and feedback is
provided to the patient regarding these measurements. Biofeedback-mediated stressmanagement (BFSM) is an education and training protocol consisting of a biofeedback
therapist educating patients regarding the link between stress, autonomic dysfunction, and
disease states. The therapist assists participants with learning stress-management
techniques and relating those techniques to physiological parameters illustrated by real
time feedback. The individual, with coaching by the biofeedback therapist, learns to alter
his/her physiology in a healthier direction with the aid of stress-management techniques
and physiological feedback (Moravec, 2011).
Patients with chronic disease and autonomic dysfunction have responded
favorably to various relaxation protocols including biofeedback. The common
mechanism underlying these various modalities may be their effects on the autonomic
nervous system, in that they induce parasympathetic control and reduce sympathetic
8

arousal. There has been some question given the efficacy of various relaxation modalities
as to whether these are sufficient without biofeedback and if biofeedback adds anything
above and beyond relaxation. After all, why add machines if one can achieve the same
results using just the body and mind? In two separate studies, Blanchard et al. (1982)
found that chronic headache sufferers, who did not respond to relaxation training,
consisting of progressive relaxation and deep breathing, demonstrated a significant
response to both EMG and thermal biofeedback. Patients receiving biofeedback were
instructed to find individual self-regulation techniques that worked for them but
encouraged to use relaxation and imagery. Therefore, these studies were not a direct
comparison between biofeedback alone and relaxation alone but were taking groups of
participants that did not respond to relaxation alone and adding biofeedback. The results
indicate that for at least certain patients under certain circumstances biofeedback can add
something to relaxation that produces superior outcomes to relaxation alone. One
argument for the efficacy of adding biofeedback to relaxation training is that it takes
away the guess work because patients know from the feedback whether they are correctly
altering the physiology in a healthy direction. This increased precision shortens the
learning curve over trial and error and reinforces the response making reliable learning
possible. Feedback can also give the patient more confidence in both the process and
their own abilities when they can actually see results in real time. Furthermore, a trained
biofeedback therapist is able to assess though the instrumentation how a participant is
performing and help them adjust techniques. Patients undergoing BFSM receive training
in a variety of different relaxation techniques combined with physiological feedback in a
working relationship with a trained biofeedback therapist. Biofeedback-assisted stress
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management (BFSM) protocol may help patients better regulate their ANS through
learning relaxation techniques that engage the parasympathetic branch and disengage the
often overactive sympathetic nervous system. This is expected to increase balance of the
ANS and lead to better health outcomes.

Efficacy of Biofeedback
In a comprehensive review of the literature, Yucha and Montgomery (2008)
determined that biofeedback has demonstrated efficacy in the treatment of a number of
diseases and conditions including anxiety, attention deficit hyperactivity disorder
(ADHD), chronic pain, epilepsy, constipation, adult headache, hypertension, motion
sickness, Raynaud’s disease, temporomandibular disorder (TMD), and urinary
incontinence particularly in females. The authors indicated that lack of demonstrated
efficacy of biofeedback, with regards to particular illnesses, should not be taken as a
demonstrated lack of efficacy, because a number of the reviewed diseases included few
studies, poorly designed research, and/or mixed results (Yucha & Montgomery, 2008).

Training Acquisition
One issue with assessing outcomes in biofeedback is that it cannot be assumed
that all participants received the same “dose.” In a drug study, for example, participants
receive a set measurable dose. In a biofeedback experiment, or in clinical practice, it is
reasonable to believe that there are individual differences in ability, belief, amount of
practice, and other such variables that would result in some people being more successful
10

at learning biofeedback than others. It is also reasonable to believe that these differences
in learning would be related to health outcomes.
Yucha and Montgomery (2008) make a distinction between training and
treatment. An individual receiving treatment, under the care of a medical professional, is
often a passive recipient. Other than compliance with the treatment, such individuals are
not expected to do anything in particular for the treatment to be effective. Conversely,
training connotes active participation in which an individual must learn, practice, and
master something. It necessarily follows that there would be individual differences in
ability, motivation, practice, and subsequently success in learning and application.
Biofeedback can be considered training rather than a treatment and effective biofeedback
necessitates learning and skill acquisition on the part of the participant (Yucha &
Montgomery, 2008).
There is evidence to support the effectiveness of biofeedback. However, there are
some mixed results within the literature as well. Some of this variability may be due to
researchers not taking into account the extent of training acquisition, or whether or not
participants had successfully learned to alter their physiology, especially in the absence
of feedback. It is one thing to be able to successfully modify one’s physiology when
presented with immediate feedback and coached by a trained therapist, but quite another
is to be able to draw upon a learned skill in the absence of feedback, and ultimately in
real life outside of the therapy room or laboratory. Failure to assess whether or not
participants are able to successfully alter their physiology after receiving a biofeedback
intervention is tantamount to not assessing whether participants actually received the
intended treatment or the same “dose” of the treatment. Therefore, some measurement of
11

training criteria indicative of meaningful physiological change or training acquisition
should be included in biofeedback studies. However, this is often not the case (Yucha &
Montgomery, 2008).

Current Thesis
The current work tests the effects of BFSM vs. UC on health outcomes in patients
with chronic illnesses that are known to involve ANS dysregulation and higher levels of
depression. It is predicted that BFSM will lead to lower levels of depression, and
norepinephrine as a marker of sympathetic nervous system activity, which is known to be
over-active in patients with ANS dysfunction. A measure of training acquisition was also
developed. This is a continuous measure of the magnitude of change in HRV from a prerandomization physiological monitoring period of self-relaxation without feedback, to a
post intervention or usual care self-relaxation physiological monitoring period. This
training acquisition measure indicates the relative extent to which participants are able to
regulate their ANS in the absence of feedback. It is hypothesized that training acquisition
will act as a moderator to the main effect of BFSM vs. UC in predicting the health
outcomes of depression and norepinephrine levels.
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CHAPTER II

METHODS

Participants
Participants were 37 chronic disease patients with either CAD or MS already
receiving treatment at the Cleveland Clinic Foundation (CCF). Since these diseases both
involve dysfunction of the ANS, all patients were analyzed together. Inclusion criteria
included being between the ages of 18 and 90, the ability to give informed consent, no
significant cognitive impairment, no pacemakers or defibrillators, and the ability to attend
10 study sessions.

Equipment
Non-invasive physiological monitoring was conducted via EKG pads placed on
the forearm for use in calculating HRV. HRV was used as the primary measure of
physiological arousal because it is a known measure of ANS balance.1 (bottom, page 14)
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Norepinephrine, as a marker of autonomic activity, was assessed as an outcome
variable. Venous blood was drawn for analysis of norepinephrine. Depression was also
measured as an outcome variable using the Patient Health Questionnaire Depression
Scale (PHQ-8). The PHQ-8 is an eight item screen for depression with demonstrated
reliability and validity (Pressler et al., 2010). 2 Four patients were excluded from the
analyses utilizing norepinephrine as an outcome variable due to issues with data
collection. The nurse was unable to draw blood for these patients for analysis of plasma
norepinephrine. Therefore, while N = 37 for analysis of depression, N = 34 for analysis
of norepinephrine.

Design and Procedure
The design is a randomized, controlled study of biofeedback-assisted stress
management (BFSM) vs. usual care (UC) in patients with chronic disease (CAD and
MS). 3 Effects of BFSM vs. UC on depression and activity of the sympathetic branch of
1

Other physiological measures that were recorded, but that are beyond the scope of this
thesis, include respiration rate, skin conductance, digital peripheral temperature, and
electromyography.

2

Other measures beyond the scope of the current work were collected including
epinephrine and various inflammatory markers and other questionnaires (i.e., SF36,
LET, GAD-7).

3

The study, including design and data collection, was previously conducted by the
Moravec Lab at CCF. It is described here to introduce the data that will be analyzed.
14

the ANS were assessed. Training acquisition was tested as a moderator of the effects of
BSFM vs. UC on depression and ANS function. All participants underwent an initial
study visit during which they were asked to complete the PHQ-8 depression scale as well
as demographic data (Table 1.) Venous blood was then drawn to measure catecholamines
(i.e., norepinephrine) as a measure of ANS function, specifically activation of the
sympathetic nervous system.
Following the blood draw, Non-invasive physiological monitoring of HRV was
conducted, for all participants, during a five minute self-relax period. During this selfrelax period patients did not receive any external feedback regarding their physiology. At
the end of the initial study visit, participants were randomly assigned to either a BFSM
treatment group or a UC control group. Figure 1 outlines the overall study design.
Following randomization, the UC control group continued to receive their usual standard
treatment from their physician(s) at the Cleveland Clinic as indicated by the standard of
care for their disease and their individual condition. Participants were asked to inform
research personnel if they enrolled in any other relaxation, stress management, or
psychotherapy interventions including biofeedback. Zero participants in the UC control
group received any type of biofeedback intervention during the course of the study.
The BFSM treatment group also continued to receive usual care from their
physicians(s) at the Cleveland Clinic after randomization and for at least the duration of
the study. In addition to usual care, the BFSM treatment group also received eight
weekly sessions of BFSM with a board certified biofeedback therapist certified through
the Biofeedback Certification International Alliance. During the 8 week BFSM
15

Table 1. Demographic Data Total Sample
N

37

Sex (Female/total)

20/37

Race (Caucasian/total)

24/37

Age (years)*

56 ± 11

Disease duration (years)*

8±9

*Data presented as mean ±SD.
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Initial Study Visit (All participants)
•
•
•
•

Demographics
PHQ-8
Blood Draw
Physiologic Monitoring
(5 min. self-relax without feedback)

Randomization

UC

BFSM

Intervention

Intervention

Usual Care

Usual Care +
8 weeks BFSM

Final Study Visit (All participants)
•
•
•
•

Demographics
PHQ-8
Blood draw
Physiologic Monitoring
(5 min. self-relax without feedback)

Figure 1. Overall Study Design
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intervention patients received non-invasive physiological monitoring of digital peripheral
temperature, and Galvanic skin conductance via finger sensors; surface muscle tension
via EMG; respiration via a respiratory strain gauge; and EKG for use in calculating HRV.
Participants received visual feedback regarding these physiological parameters by
computer. Patients were educated about the connection between these physiological
parameters, the stress response, the relaxation response, the ANS, and disease symptoms
and progression. Participants were taught a number of relaxation techniques including
various breathing techniques (i.e., diaphragmatic breathing, resonant frequency
breathing), progressive muscle relaxation, guided imagery, autogenics, mindfulness,
positive affirmations, and cue-controlled relaxation as well as how these techniques relate
to the physiological feedback. Patients were coached regarding how to use the relaxation
techniques and feedback to move their physiology in a healthy direction. They were also
given a finger thermistor and instructed to practice finger warming at home. Within the
standardized protocol a lot of room was given for individual differences in instruction as
fits the BFSM model. For example, patients were trained first on the physiological
parameter that appeared most reactive and salient for each individual.
After eight weeks of either BFSM or UC, all participants in both groups returned
for a final study visit. The final study visit followed the exact same protocol as the initial
study visit with all of the same measures being assessed as before, including
questionnaires, blood draws, and physiological monitoring.

18

Data Analysis
Training acquisition was assessed by the magnitude of change in mean HRV from
the initial study visit five minute self-relax period to the final study visit five minute selfrelax period. This was therefore, a measure of the extent to which participants learned to
regulate their physiology in the absence of feedback. HRV was measured by the Standard
Deviation of the Inter-Beat Interval (SDNN) because it is a widely used measure in both
the psychology and cardiology literature and due to its relative clarity of interpretation.
Data analyses were conducted using 2 (Group: BFSM, UC) X Training
Acquisition (continuous) moderated multiple regression analyses for each outcome
variable, depression and norepinephrine. Data collected at the final study visit for both
depression and norepinephrine were used in these analysis. Methods prescribed by Aiken
and West (1991) were followed to regress depression and norepinephrine on trainingacquisition (continuous) X 2 (BFSM vs. UC) group. Centered training-acquisition scores
and the dummy coded group variable were entered first as main effects, and their product
was entered second as the interaction term.
Post hoc analysis of interactions was carried out by simple slopes analysis (Aiken
& West, 1991). Simple slopes for the regression of training acquisition on both
depression and norepinephrine were tested at the two different group levels: BFSM
treatment group and UC control group. The relationships between group assignment and
depression and group assignment and norepinephrine were assessed at different levels of
the moderator variable, training acquisition. These levels included the mean level of
training acquisition as well as one standard deviation above and one standard deviation
below the mean.
19

CHAPTER III

RESULTS

Normality of the distributions of the predictor variable training acquisition and the
outcome variables norepinephrine and depression were assessed graphically using
histograms and P-P plots and numerically using skew and kurtosis statistics as well as the
Kolmogorov-Smirnov test. Skewness and kurtosis values were converted to Z scores and
tested for significance against tables of the standard normal distribution. For training
acquisition, while the distribution showed evidence of negative skew (-.156) and negative
kurtosis (-1.037), neither of these were significantly greater than 0. The KolmogorovSmirnov test further indicated that training acquisition did not deviate significantly from
normal (D [33] = .104, p=.200). Norepinephrine showed evidence of slightly significant
positive skew (Z=1.96, p < .05) as well as non-significant positive kurtosis (Z=.107).
However, the results of the Kolmogorov-Smirnov (D [37] = .106, p =.200) indicated that
norepinephrine scores did not deviate significantly from normal. Depression scores (D
[37] = .197, p =.001) were significantly non-normal, showing significantly positive skew
20

(Z = 3.64, p < .05) and significantly positive kurtosis (Z= 2.20, p < .05). Due to the
sample size of this study no transformations were carried out. Levine’s test was used to
assess homogeneity of variance. The variances for the BFSM group and the UC group
were not significantly different for norepinephrine (F [1, 3] = .007, p = .936) or
depression (F [1, 35] = .2.680, p = .111). Predictor variables were assessed for
multicollinerity. Treatment and training acquisition were not highly correlated (r = .037).

Norepinephrine
Replicating prior research, BFSM was associated with significantly less plasma
norepinephrine in comparison to UC (t [31] = -2.485, β = -.408, p = .019) (Table 2).
There was not a significant main effect of training acquisition on norepinephrine (F [1,
31] = .265, R2= .008, p = .610) While the model was not significant, there was a very
small non-significant trend indicating that a 1 unit raw score increase in trainingacquisition is associated with a 1.052 unit raw score decrease in norepinephrine or a 1
standard deviation increase in training acquisition is associated with .092 standard
deviation decrease in norepinephrine (Table 2).
For norepinephrine, the training acquisition X BFSM (vs. UC) interaction was not
significant (F [1, 29] = .156, R2 = .004, p = .696) (Table 3). As displayed in Figure 2,
among those with lower (-1SD) training-acquisition, norepinephrine was lower in the
BFSM condition (M = 345.048, SD = 60.084) compared to the UC condition (M =
478.659, SD= 63.853) (t [35] = 1.515, β = .343, p = .141). Among those with higher
(+1SD) training-acquisition, norepinephrine was lower in the BFSM condition (M =
307.840, SD= 58.803) compared to the UC condition (M = 493.374, SD = 79.410) (t [35]
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Table 2. Main Effects of BFSM vs. UC on Norepinephrine

BFSM
TA

B

SE B

β

p

-158.64

63.83

-.41

.019

-1.05

2.04

-0.92

.610
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Table 3. Interaction of BFSM vs. UC and Training Acquisition on Norepinephrine

BFSM X TA

F

R2

p

.156

.004

.696
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Figure 2. Norepinephrine in the BFSM and UC groups at different
levels of training acquisition. n = number of UC participants / number of
BFSM participants.
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= .878, β = .477, p = .071 (Figure 2). Simple slopes analysis revealed that, in the UC
condition, training acquisition was not significantly related to norepinephrine (t[13] =
.145, β = .039, p= .886). A small non-significant trend indicates that for the UC group,
higher levels of training acquisition are related to higher levels of norepinephrine, such
that a 1 unit raw score increase in training-acquisition is associated with a .443 unit raw
score increase in norepinephrine and a 1 standard deviation increase in training
acquisition is associated with an increase in .039 standard deviation units on
norepinephrine. In the BFSM condition, training acquisition was also not significantly
related to norepinephrine (t[19] = -.445, β = -.098, p = .659). However, a non-significant
trend shows that higher training-acquisition is related to lower norepinephrine, such that a
1 unit raw score increase in training-acquisition is associated with a -1.121 unit raw score
decrease in norepinephrine and a 1 standard deviation increase in training

Depression
As demonstrated in Table 4, there was no main effect of BFSM on depression (F
[1, 35] = 2.799, R2= .074, p = .103). However, a non-significant trend indicates that a
change from the UC condition to the BFSM condition is associated with a 2.690 unit raw
score increase in depression or a .272 standard deviation increase in depression.
Additionally, there was no main effect of training-acquisition on depression (F [1, 35] =
.041, R2= .001, p = .841). However, a non-significant trend indicated that a 1 unit raw
score increase in training-acquisition is associated with a .010 unit raw score increase in
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Table 4. Main Effects of BFSM vs. UC on Depression

b

SE B

β

p

BFSM

2.69

1.61

0.27

.103

TA

0.01

0.05

0.03

.841
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depression and a 1 standard deviation increase in training-acquisition is associated with
an increase in .034 standard deviations on depression (Table 4).
For depression, the training acquisition X BFSM (vs. UC) interaction was not
significant (F [1, 33] = .138, R= .004, p = .713) (Table 5). As displayed in Figure 3,
among those with lower (-1SD) training-acquisition, depression was higher in the BFSM
condition (M = 5.741, SD= 1.637) compared to the UC condition (M = 2.438, SD =
1.693) (t[35] = 1.403, β = .334, p = .17). Among those with higher (+1SD) trainingacquisition, depression was higher in the BFSM condition (M = 5.428, SD= 1.582)
compared to the UC condition (M = 3.375, SD=1.761) (t[35] = .867, β = .208, p = .392)
(Figure 3). Simple slopes analysis revealed that, in the UC condition, training acquisition
was not significantly related to depression (t [17] = .373, β = .094, p = .711). However,
there was a non-significant trend indicating that depression was higher in the UC group at
higher levels of training acquisition. Among those in the UC condition, a 1 unit raw
score increase in training-acquisition is associated with a .028 unit raw score increase in
depression or a 1 standard deviation increase in training acquisition is associated with an
increase in .094 standard deviation units on depression. In the BFSM condition, training
acquisition was also not significantly associated with depression (t [19] = -.139, β = -.03,
p = .89). However, there was a non-significant trend indicating that in the BFSM
condition, higher levels of training acquisition were associated with lower levels of
depression. Among those in the BFSM condition, a 1 unit raw score increase in trainingacquisition is associated with a -.009 unit raw score decrease in depression or a 1
standard deviation increase in training acquisition is associated with an decrease in -.03
standard deviation units on depression.
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Table 5. Interaction of BFSM vs. UC and Training Acquisition on Depression

BFSM X TA

F

R2

p

.138

.004

.713
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Figure 3: Depression in the BFSM and UC groups at different levels of
training acquisition. n = number of UC participants / number of BFSM
participants
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CHAPTER IV

DISCUSSION

Norepinephrine
As predicted, BFSM was associated with significantly less norepinephrine than
UC. This result is in line with previous research. Mathew et al. (1981) demonstrated
significant reductions in plasma norepinephrine in a biofeedback-assisted relaxation
group compared to a control group in patients with generalized anxiety disorder. 52
Hypertensive patients treated with biofeedback-assisted relaxation showed significant
reductions in plasma norepinephrine in comparison to a control group (McCoy et al.,
1988).
The present study extends the literature to two diseases, CAD and MS that have
been less frequently studied. Both CAD and MS are characterized by dysregulation of
the autonomic nervous system (ANS). Patients with both diseases tend to have increased
sympathetic nervous system activation and decreased parasympathetic nervous system
activity. Autonomic dysregulation of this type is related to worse health outcomes in both
CAD and MS (Carney et al., 2005; Merico et al., 2005). High levels of plasma
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norepinephrine can arise from over activation of the sympathetic nervous system and is
an independent predictor of negative health outcomes (Goldstein et al., 1983).
In the current study, at the first study visit assessment prior to randomization the
mean level of norepinephrine for the whole sample was 393.1 picograms per milliliter
(pg/ml) with a standard deviation of 195.3 pg/ml and a range of 750.0 pg/ml. At time 1
those patients eventually randomized to the UC control condition had a mean level of
norepinephrine of 460.0 pg/ml with a standard deviation of 211.3 pg/ml and a range of
915 pg/ml. Those patients eventually randomized to the BFSM group stared the study
with a mean level of norepinephrine 364.2 pg/ml with a standard deviation of 187.6
pg/ml and a range of 660 pg/ml. Norepinephrine levels at the final study visit (second
assessment) were used in the data analysis for the current in the comparison between
groups after the intervention. At this time point, the mean norepinephrine level for the
entire sample (both groups) was 393.1 pg/ml with a standard deviation of 195.3 pg/ml
and a range 750.0 pg/ml. The mean level of norepinephrine for the UC was 484.4 pg/ml
with a standard deviation 180.0 pg/ml and a range of 607.0 pg/ml. The BFSM group had
a mean norepinephrine level at time 2 of 326.0 pg/ml with a standard deviation of 182.2
pg/ml and a range of 750.0 pg/ml. The UC group had a mean increase in norepinephrine
from the first study visit to the final study visit of 15.6 pg/ml with a standard deviation of
158.3 pg/ml and a range of 510 pg/ml. The BFSM group had a mean decrease in
norepinephrine of 38.4 pg/ml with a standard deviation of 149.1 pg/ml and a range of
553.0 pg/ml.
Cameron et al., (1986) found a range of plasma norepinephrine in healthy
unstressed participants of 150 pg/ml to 250 pg/ml over 24 hours. The authors indicated
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that this in the lower end of the range of norepinephrine levels reported in the literature in
healthy participants. Additionally, healthy subjects demonstrated an increase in
norepinephrine of 44 pg/ml in response to laboratory stressors
The results of the current study with regards to norepinephrine provide further
support for the hypothesis that BFSM may act as a buffer to the over-activation of the
sympathetic nervous system observed in diseases such as CAD and MS involving
autonomic dysfunction. Demonstration of enhanced ability to regulate physiology
towards better autonomic balance in both MS and CAD patients is further evidence of a
common mechanism.
The common mechanism may be relaxation leading to healthier autonomic
balance with increased parasympathetic control and decreased sympathetic activation as
evidenced in the current study by reduced norepinephrine levels. Reduced norepinephrine
has been observed in response to other stress reduction interventions other than
biofeedback. In-patient heart failure patients demonstrated a mean reduction in
norepinephrine of 232.4 pg/ml during a12-minute visit with a therapy dog and 240.1 after
the visit. These reductions were significant in comparison to two control groups, one
receiving a12-minute visit from a human volunteer and another group receiving usual
care (Cole et al., 2007). In a randomized controlled study, meditation was shown to
significantly increase subjective quality of life and decrease plasma norepinephrine in
elderly patients with heart failure. The meditation group significantly decreased mean
plasma norepinephrine from 677.7 pg/ml with a standard deviation of 96.6 pg/ml to 387.1
pg/ml with a standard deviation of 39.1 pg/ml .The control group decreased

32

norepinephrine from 491.4 with a standard deviation of 35.9 to 470.6 with a standard
deviation of 31.2. This change was not statistically significant.
There is some evidence that biofeedback may provide different benefits to
relaxation alone. McCoy et al., (1988) compared thermal biofeedback to progressive
muscle relaxation without feedback in hypertensive individuals. Patients assigned to the
biofeedback group demonstrated significant reductions in norepinephrine and mean
arterial pressure, while the patients in the relaxation group did not demonstrate any
significant changes on any variable. The mean pre-treatment plasma levels for the
biofeedback group were 277.4 pg/ml supine with a standard deviation of 127.0 pg/ml and
589.3 pg/ml standing with standard deviation of 239.8. The mean post-treatment plasma
norepinephrine levels for this group were 221.7 pg/ml supine with a standard deviation of
98.2 pg/ml and 509.0 pg/ml standing with a standard deviation of127.6 pg/ml. For the
relaxation group, the mean pre-treatment plasma norepinephrine were 224 pg/ml supine
with a standard deviation of 130.0 pg/ml and 545.0 pg/ml standing with standard
deviation of 280.3. The post-treatment norepinephrine levels for this group were 210.3
pg/ml supine with a standard deviation of 104.8 pg/ml and 496.5 pg/ml standing with a
standard deviation of 248.1. One benefit of BFSM above and beyond other relaxation or
stress management interventions is that the patient is trained to alter their own physiology
in a healthy direction rather than just provided with an intervention that is done to them.
In the current study, BFSM participants demonstrated significant reductions in plasma
norepinephrine after being trained in various relaxation modalities augmented by
feedback. The plasma norepinephrine was not drawn during a feedback session but after
the 8 week intervention was completed. More studies are needed directly comparing
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relaxation protocols alone to relaxation with biofeedback and investigating the
mechanisms both physiological and psychological that account for successful outcomes.
Patients receiving biofeedback may differentially benefit from the intervention
depending on how successful they are in acquiring the ability to change their physiology
in a positive direction. Individual characteristics such as motivation, ability, and amount
of practice outside of biofeedback sessions are just some of the variables that could
influence learning and performance differences. This leads to uncertainty that all of the
participants received the exact same “dose” of biofeedback since dosing cannot be as
tightly controlled as in pharmacological studies. Therefore, a training acquisition measure
was introduced in this proposal.
There was no main effect of training acquisition on norepinephrine. There was
however, a non-significant trend demonstrating that an increase in training acquisition is
related to a decrease in norepinephrine, such that a 1 unit raw score increase in training
acquisition is associated with a1.052 unit raw score decrease in norepinephrine and a 1
standard deviation increase in training acquisition is associated with a .092 standard
deviation decrease in norepinephrine. However, an effect size of.092 is miniscule and
does not really reflect a meaningful effect.
The training acquisition measure was conceptualized as a measure of the relative
extent to which participants are able to move their physiology in a healthy direction in the
absence of feedback. It is based on how well participants were able to raise their HRV
during a self-relax period without feedback. This was measured prior to and after the
eight week biofeedback intervention period in both the BFSM treatment and UC control
groups. The magnitude of change in HRV from pre-assessment to post-assessment was
34

operationalized as a measure of training acquisition. Patients being able to raise their
HRV in the absence of feedback points to training transfer outside the biofeedback
session and without a biofeedback therapist to coach them and is therefore indicative of
physiological self-regulation. The patients in this study demonstrated a mean decrease in
HRV of 1.2 ms with a standard deviation of 16.6. While the UC group demonstrated a
mean decrease of 3.0, the BFSM group had a mean increase in HRV of .40 ms. Clearly,
there was a lot of variability among patients in their level of training acquisition. In a
comprehensive review of the literature regarding changes in HRV from exercise, drug,
and biobehavioral interventions, including biofeedback, (Nolan et al., 2008) found an
overall magnitude of change equivalent to an increase of 9.0 ms .
It was hypothesized that training acquisition would moderate the relationship
between group assignment (BFSM vs. UC) and ANS function, as measured by
norepinephrine.
There was not a significant interaction between training acquisition and group
assignment. Analyzing the data at different levels (±1SD) of training acquisition
demonstrated that for participants with both lower and higher levels of training
acquisition, norepinephrine was lower in the BFSM condition compared to U.C.,
reflecting the lack of interaction and essentially recapitulating the main effect of BFSM
on norepinephrine. In other words, norepinephrine was lower in the BFSM group then
the UC group regardless of the effect of training acquisition
Simple slopes demonstrated that training acquisition was not significantly related
to norepinephrine in either the UC or BFSM condition. However, analysis of simple
slopes revealed small non-significant trends in opposite directions among the UC and
35

BFSM groups. While in the UC group, higher levels of training acquisition are related to
higher levels of norepinephrine, in the BFSM group higher levels of training acquisition
are related to lower levels of norepinephrine. The demonstrated effects, however, are not
much different from 0. For the UC group, a 1 unit raw score increase in training
acquisition is associated with a.443unit raw score increase in norepinephrine and a 1
standard deviation increase in training acquisition is associated with an increase in .039
standard deviation units of norepinephrine For the BFSM group, a 1 unit raw score
increase in training-acquisition is related to a 1.121 raw score decrease in norepinephrine
and a 1 standard deviation increase in training acquisition is associated with a decrease
in.098 standard deviation units of norepinephrine.
Given that those in the BFSM group had significantly less norepinephrine than the
UC group but training acquisition, as conceptualized in this study, did not moderate the
effects of group assignment on norepinephrine, it could be that just participating in
BFSM is sufficient without demonstrating training acquisition. Biofeedback could also
work through mechanisms other than relaxation leading to better ANS balance. The
paucity of evidence for this hypothesis could alternatively be attributed to the method in
which training acquisition was measured. Future studies may consider whether there is a
better way to measure a training acquisition effect.

Depression
CAD and MS patients tend to have higher levels of depression (Carney et al.,
2005; Siegert & Abernathy, 2005). Depression is related to lower survival rates among
patients with CAD (Carney et al, 205). Furthermore, depressed individuals with or
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without CAD have higher levels of norepinephrine and lower HRV (Carney et al., 2005).
Autonomic dysfunction is observed in depressed individuals who are physically healthy,
as well as in MS and CAD patients, regardless of depression. However, patients with
these types of chronic illnesses are more prone to depression than physically healthy
individuals. Therefore, it is possible, but untested, that depression may compound the
autonomic dysfunction already occurring in MS and CAD, leading to particularly
negative health consequences. Carney et al. (2005) propose that autonomic dysregulation
may mediate the link between depression and negative health outcomes in CAD. In the
current study, in addition to improving autonomic nervous system balance, it was
hypothesized that BFSM would lead to lower levels of depression compared with UC.
There was no significant main effect of group assignment on depression.
However, a non-significant trend indicated that being assigned to the BFSM group was
related to increased depression compared to being randomized to the UC group. The
regression coefficients demonstrated that going from the UC condition to the BFSM
condition is associated with a 2.690 unit raw score increase in depression or a .27
standard deviation unit increase in depression. Even though the main effect did not reach
statistical significance, it is concerning that contrary to expectations the trend indicates
that those in the BFSM group actually experienced increased depression in comparison to
the UC control group. The question arises as to whether this is an accurate and
meaningful effect and how to interpret this in light of the existing biofeedback literature
and clinical considerations. Can biofeedback, under certain circumstances, actually lead
to more negative outcomes such as increased depression?
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There is an extensive literature demonstrating the positive benefits of biofeedback
in the treatment of depression. Karavidas et al. (2007) conducted 10 sessions of HRV
biofeedback with patients meeting diagnostic criteria for major depressive disorder
(MDD). Participants demonstrated significant reductions in depression with a very large
effect size d = 3.6. Patients also significantly increased SDNN. A limitation of this study
was a lack of control group. In a comparison of depressed patients vs. healthy controls,
HRV biofeedback significantly decreased symptoms of depression and anxiety, and
increased HRV among depressed patients (Siepmann et al., 2008). Biofeedback has led to
significant reductions in depression in a number of different patient populations,
including illnesses involving autonomic dysregulation. Furthermore, HRV biofeedback
appears to attenuate the effects of depression by increasing parasympathetic control. An
intervention using respiratory sinus arrhythmia (RSA) biofeedback to increase
parasympathetic control by increasing vagal tone decreased depressive symptoms in
patients who recently underwent cardiac surgery compared to patients who received
treatment as usual (Patron et al.2013). In a pilot study conducted by Hassett et al. (2007)
twelve women with fibromyalgia, an illness believed to be at least partially related to
autonomic dysfunction, underwent 10 weeks of HRV biofeedback, after which they
demonstrated significant decreases in depression and pain, and increased overall
functioning. Patients with neurocardiogenic syncope, a syndrome characterized by
autonomic dysfunction, demonstrated significantly decreased depression, headache, and
loss of consciousness in comparison to a medication only control group after 10 sessions
of biofeedback-assisted relaxation therapy (McGrady et al., 2003).
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To this author’s knowledge, there have not been published studies demonstrating
increased depression as a result of biofeedback. Taken together with the numerous
published studies with positive results of biofeedback in the reduction of depression
among a variety of different population leads one to question the effect observed in this
study sample as being representative of a true population effect. An effect size of .27 is
considered a small effect size (Cohen, 1992). Being assigned to the BFSM group as
opposed to the UC group was associated with a raw score increase of 2.7. The PHQ-8
consists of 8 items with a score range of 0-24. Scores below 5 are considered as no
depressive symptoms. Scores of five to nine indicate mild depression, while scores above
10 indicate moderate depression, and scores higher than 15 are indicative of clinical
depression (Pressler et al., 2011). In the current study, for the total sample at the initial
study visit the mean score on the PHQ-8 was 4.86 with a standard deviation of 4.93 and a
range of 16. The BFSM group at time 1 had a mean score on the PHQ-8 of 6.11 with a
standard deviation of 5.4 and a range of 16. The UC group at the first study visit had a
mean of 3.7 with a standard deviation of 4.1 and a range of 12. The PHQ-8 administered
at the final study visit was bused for comparison between the groups in this study. By the
time of this final study visit, participants had been randomized to the BFSM group or the
UC group and the intervention carried out. At this second administration, the mean score
on the PDQ-8 for the total sample was 4.3 with standard deviation of 5 and a range of 20.
The UC group at time 2 had a mean PDQ-8 score of 2.9 with a standard deviation of 3.8
and a range of 15. The BFSM group had a mean score of 5.6 with a standard deviation of
5.7 and a range of 20. Rather than concluding that BFSM increases depression compared
to UC, with a non-significant p-value of .103, the more probable explanation is that the
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effect was due to chance and is not representative of a true population value. Alternately,
the higher levels of depression in the BFSM group as compared to the UC group at the
final study visit may be due to the fact that this group had much higher depression scores
at the baseline assessment. The regression analyses in this study were only carried out on
time 2 values. It could be that the BFSM group was by chance more depressed coming
into the study and that randomization was not entirely successful with regards to
depression.
There was additionally no main effect of training-acquisition on depression.
However, a non-significant trend demonstrated that an increase in training-acquisition is
related to an increase in depression, such that a 1 unit raw score increase in training
acquisition is associated with a .10 unit raw score increase in depression and a 1 standard
deviation increase in training acquisition is associated with an increase in 0.32 standard
deviation units on depression.
For depression, the interaction between group and training acquisition was also
not significant. Post-hoc analysis showed that depression was higher in the BFSM
condition than the UC condition among both participants with both higher (+1SD) and
lower (-1SD) levels of training acquisition, again reflecting the lack of interaction.
Simple slopes demonstrated that training acquisition was not significantly related
to depression in the UC or BFSM conditions. However, analysis of simple slopes
indicated non-significant trends in varying directions among the UC and BFSM groups.
In the UC condition depression was higher at higher levels of training acquisition.
Conversely, for the BFSM condition higher levels of training acquisition were related to
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lower levels of depression. For the UC condition, a 1 unit raw score increase in trainingacquisition is associated with a 0.28 unit raw score increase in depression and a 1
standard deviation increase in training-acquisition is associated with an increase in
0.94standard deviation units on depression. In the BFSM condition, a 1 unit raw score
increase in training-acquisition is associated with a .009 unit raw score decrease in
depression and a 1 standard deviation decrease in training-acquisition is associated with a
.03 standard deviation decrease in depression. The non-significant and contrary results
for training acquisition and the interaction between group and training acquisition for
depression are difficult to interpret in light of the small effect sizes except to state that
they are not generalizable.
Limitations of this study include a small sample size. The small sample size did
not allow enough power to analyze the CAD and MS groups separately. Although, it is
reasonable to assume a common mechanism for these diseases due to the commonality of
ANS dysregulation, there could be differences between the groups based on differing
disease profiles. Also, results from the CAD and MS patients taken together may not
generalize to other chronic diseases, particularly those that do not involve ANS
dysregulation. In order to study these potentially different populations, it may be
necessary to use different outcome measures and training acquisition criteria that do not
have an underlying assumption of working through the ANS. Different types of diseases
could potentially work within models of biofeedback other than BFSM, which has an
underlying assumption that learning relaxation techniques with feedback will lead to
better self-regulation of the ANS and hence better health outcomes. Further research is
needed with larger sample sizes and different patient groups, both with other diseases
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having known ANS dysfunction, as well as those without particular ANS involvement.
Further research is also needed to delineate the precise mechanisms by which
biofeedback might exert an influence on the ANS, as well as other pathways that may
lead to subsequent health outcomes.
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